All In Biotech

Drug Trial Radar · NCT07581951

A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of HSK31679 in Patients With Metabolic Dysfunction Associated Steatohepatitis (MASH)

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 886 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

886

Planned (sponsor's estimate)

Start

Jun 30, 2026

Primary completion

Jun 30, 2029

Study completion Dec 30, 2032

Sponsor

Sponsor type
Industry
First posted
May 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of HSK31679 compared to placebo in patients with metabolic dysfunction-associated steatohepatitis (MASH) .

Conditions

  • MASH - Metabolic Dysfunction-Associated Steatohepatitis
  • NASH (Non-Alcoholic Steatohepatitis)

Interventions

  • HSK31679Drug

    tablet

  • PlaceboDrug

    Matching tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Resolution of Steatohepatitis Without Worsening of Fibrosis at Week 52.Time frame: Week 52
  2. Number of Participants With at Least an Improvement of Fibrosis ≥1 Stage Without Worsening of Steatohepatitis at Week 52.Time frame: Week 52
  3. Time to First Occurrence of Disease ProgressionTime frame: Up to 4.5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tsinghua Changgung Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.